TGF‐Beta Signaling in Breast Cancer
- 1 November 2006
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1089 (1) , 119-126
Abstract
Abstract: The antiestrogen tamoxifen is one of the most successful drugs in the endocrine treatment of breast cancer and significantly reduces the risk of recurrence and death. Antiestrogens act by inhibiting the production of growth‐stimulatory factors as well as by activating peptides with growth‐inhibitory effects like transforming growth factor‐ beta (TGF‐β). In hormone‐responsive breast cancer cells treatment with antiestrogens leads to the conversion of TGF‐β1 into a biologically active form. Expression of TGF‐β2 and TGF‐β receptor (TβR) II is induced via a transcriptional mechanism involving p38 MAP kinase. Inhibition of p38 abolishes antiestrogen‐dependent growth inhibition. However, the role of TGF‐β in breast cancer progression is ambiguous, as it was shown to display both tumor‐suppressing and ‐enhancing effects. A polymorphism in the promoter of TGF‐β2 that enhances expression of the protein was associated with lymph node metastasis in breast cancer patients, pointing to a role of TGF‐β2 in the process of invasion. An immunohistochemical study on TβRI and TβRII expression in breast cancer tissues indicates that the estrogen receptor (ER) status of a tumor is an important marker and a potential mediator of the transition of TGF‐β from tumor suppressor to tumor promoter. In ER‐negative tumors, expression of TβRII was associated with a subset of tumors that appeared to be highly aggressive, leading to strongly reduced overall survival times. Further characterization of the influence of ER expression on TGF‐β signal transduction shows that ER‐α plays a crucial role in TGF‐β signaling.Keywords
This publication has 27 references indexed in Scilit:
- A Novel Functional Polymorphism in theTransforming Growth Factor-β2Gene Promoter and Tumor Progression in Breast CancerCancer Research, 2006
- Antiestrogenic Regulation of Transforming Growth Factor Beta Receptors I and II in Human Breast Cancer CellsAnnals of the New York Academy of Sciences, 2006
- SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADSAnnual Review of Cell and Developmental Biology, 2005
- Non-Smad TGF-β signalsJournal of Cell Science, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell MotilityJournal of Biological Chemistry, 2004
- Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer PatientsClinical Cancer Research, 2004
- Growth factors in breast cancerEndocrine Reviews, 1995
- Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor β1 (TGF-β1): Lack of growth-inhibitory effect on cells expressing the simian virus 40 large-t antigenInternational Journal of Cancer, 1994
- The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms.Genes & Development, 1994